DE69814858D1 - Galaktose-bindende lektine konjugate mit clostridiale neurotoxine ,wie analgetika - Google Patents

Galaktose-bindende lektine konjugate mit clostridiale neurotoxine ,wie analgetika

Info

Publication number
DE69814858D1
DE69814858D1 DE69814858T DE69814858T DE69814858D1 DE 69814858 D1 DE69814858 D1 DE 69814858D1 DE 69814858 T DE69814858 T DE 69814858T DE 69814858 T DE69814858 T DE 69814858T DE 69814858 D1 DE69814858 D1 DE 69814858D1
Authority
DE
Germany
Prior art keywords
galactose
pain
agents
binding lectin
analgetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69814858T
Other languages
English (en)
Other versions
DE69814858T2 (de
Inventor
John Duggan
Andrew Chaddock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntaxin Ltd
Original Assignee
Microbiological Research Authority
Speywood Laboratory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbiological Research Authority, Speywood Laboratory Ltd filed Critical Microbiological Research Authority
Application granted granted Critical
Publication of DE69814858D1 publication Critical patent/DE69814858D1/de
Publication of DE69814858T2 publication Critical patent/DE69814858T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69814858T 1997-10-08 1998-10-07 Galaktose-bindende lektine konjugate mit clostridiale neurotoxine ,wie analgetika Expired - Lifetime DE69814858T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9721189.0A GB9721189D0 (en) 1997-10-08 1997-10-08 Analgesic conjugates
GB9721189 1997-10-08
PCT/GB1998/003001 WO1999017806A1 (en) 1997-10-08 1998-10-07 Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics

Publications (2)

Publication Number Publication Date
DE69814858D1 true DE69814858D1 (de) 2003-06-26
DE69814858T2 DE69814858T2 (de) 2004-03-11

Family

ID=10820129

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69814858T Expired - Lifetime DE69814858T2 (de) 1997-10-08 1998-10-07 Galaktose-bindende lektine konjugate mit clostridiale neurotoxine ,wie analgetika

Country Status (13)

Country Link
US (2) US7052702B1 (de)
EP (1) EP0996468B1 (de)
JP (1) JP4629225B2 (de)
AT (1) ATE240747T1 (de)
AU (1) AU741456B2 (de)
CA (1) CA2306350C (de)
DE (1) DE69814858T2 (de)
DK (1) DK0996468T3 (de)
ES (1) ES2198750T3 (de)
GB (1) GB9721189D0 (de)
PT (1) PT996468E (de)
WO (1) WO1999017806A1 (de)
ZA (1) ZA989138B (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US8012491B2 (en) * 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US20040071736A1 (en) * 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US20080249019A1 (en) * 1998-08-25 2008-10-09 Syntaxin, Ltd. Treatment of mucus hypersecretion
GB9907429D0 (en) * 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US20090018081A1 (en) * 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
EP2267008B1 (de) 1999-08-25 2014-07-02 Allergan, Inc. Aktivierbare rekombinante Neurotoxine
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells
JP4991073B2 (ja) * 1999-12-02 2012-08-01 シンタキシン リミテッド 神経細胞への治療薬の送達のための構築物
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
AU4904101A (en) * 1999-12-08 2001-07-09 Fluoro Probe, Inc. Method for relieving pain associated with an internal disease site
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
AU2001270219A1 (en) * 2000-06-28 2002-01-08 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
GB0108332D0 (en) * 2001-04-03 2001-05-23 Univ Durham Lectin directed prodrug delivery system
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
GB0213383D0 (en) * 2002-06-11 2002-07-24 Cambridge Biotechnology Ltd Therapeutic conditions
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
EP1982996A1 (de) * 2004-09-01 2008-10-22 Allergan, Inc. Abbaubare Clostridientoxine
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7179474B2 (en) 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US7659092B2 (en) * 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8052979B2 (en) 2005-03-15 2011-11-08 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US8021859B2 (en) * 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US7419675B2 (en) 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
CA2657460A1 (en) 2006-07-11 2008-09-04 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
WO2008008803A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
RU2491086C2 (ru) * 2007-10-23 2013-08-27 Аллерган, Инк. Способы лечения мочеполовых-неврологических расстройств с использованием модифицированных клостридиальных токсинов
WO2011023213A1 (en) * 2009-08-28 2011-03-03 Merz Pharma Gmbh & Co. Kgaa Modified chemodenervating agents
GB201108108D0 (en) * 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
TR201802754T4 (tr) 2012-05-30 2018-03-21 Harvard College Mühendislik uygulanmış botulinum nörotoksini.
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US10087432B2 (en) * 2012-11-21 2018-10-02 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
PT3242884T (pt) 2015-01-09 2021-04-22 Ipsen Bioinnovation Ltd Neurotoxinas catiónicas
ES2895853T3 (es) 2015-03-26 2022-02-22 Harvard College Neurotoxina botulínica modificada
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (de) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Herstellung von aktivierten clostridien-neurotoxinen
CN110072880A (zh) 2016-08-24 2019-07-30 哈佛大学校长及研究员协会 工程化肉毒杆菌神经毒素
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
PL3529616T3 (pl) 2016-10-20 2024-03-18 President And Fellows Of Harvard College Testy in vitro i komórkowe do pomiaru aktywności neurotoksyn botulinowych
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3470054B1 (de) 2017-10-11 2023-09-20 Hugel Inc. Mikrostrukturformulierungstechniken für botulinumtoxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
EP3758611A1 (de) 2018-02-26 2021-01-06 Ipsen Biopharm Limited Verwendung von ultraschall zur führung der injektion von nichttoxischer protease
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
EP3660509B1 (de) 2018-11-29 2022-03-09 Hugel Inc. Zellbasiertes verfahren zur bestimmung der aktivität von botulinumtoxin
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
JP2024509634A (ja) 2021-03-30 2024-03-04 イプセン バイオファーム リミテッド 疼痛及び炎症性障害の処置
CA3213914A1 (en) 2021-03-30 2022-10-06 Mikhail KALINICHEV Treatment of pain & inflammatory disorders
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
WO2023105289A1 (en) 2021-12-06 2023-06-15 Dublin City University Methods and compositions for the treatment of pain
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792447A (en) 1981-07-23 1988-12-20 Board Of Regents, The University Of Texas System Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
WO1991009871A1 (en) 1989-12-22 1991-07-11 Seragen Incorporated Hybrid molecules having translocation region and cell-binding region
AU1582692A (en) 1991-03-08 1992-10-06 Protein Design Labs, Inc. Recombinant double chain immunotoxins
WO1993004191A1 (en) 1991-08-15 1993-03-04 Neorx Corporation Noncytolytic toxin conjugates
US5433946A (en) 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
DE4242902A1 (de) 1992-12-18 1994-06-23 Madaus Ag Verfahren zur Herstellung von Lektinkonzentraten aus Mistelextrakten und daraus hergestellte standardisierte Präparate zur Erhöhung der natürlichen Immunresistenz und für die Verwendung in der Tumor-Therapie
EP0702559B1 (de) 1993-06-10 2003-03-19 Allergan, Inc. Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
EP1757325B1 (de) 1993-12-28 2010-11-03 Allergan, Inc. Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms
JP3497554B2 (ja) 1994-03-25 2004-02-16 日本臓器製薬株式会社 新規プリン誘導体及びその薬学的に許容される塩
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
CA2191754C (en) * 1994-05-31 2000-12-12 James Oliver Dolly Modification of clostridial toxins for use as transport proteins
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
ATE366312T1 (de) 1994-10-24 2007-07-15 Ophidian Pharm Inc Impfstoff und antitoxine zur behandlung und vorbeugung von c. difficile krankheiten
US5721207A (en) * 1995-04-18 1998-02-24 Innapharma, Inc. Method for treatment of pain
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
WO1997013410A1 (en) 1995-10-13 1997-04-17 Boston Medical Center Corporation Hybrid molecules containing amidated polypeptide binding ligands
JP2000503630A (ja) * 1995-11-22 2000-03-28 ザ リサーチ アンド ディベロップメント インスティチュート，インコーポレイテッド 微生物感染症の治療用治療剤及び診断剤
US5760149A (en) 1996-08-23 1998-06-02 Elf Atochem North America, Inc. Poly(monoperoxycarbonates)
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
AU4245097A (en) 1996-08-28 1998-03-19 Ophidian Pharmaceuticals, Inc. Multivalent vaccine for (clostridium botulinum) neurotoxin
DE19735105A1 (de) 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
WO1999058571A2 (de) 1998-05-13 1999-11-18 BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
ES2275999T3 (es) 1998-07-22 2007-06-16 Osprey Pharmaceuticals Limited Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares.
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
GB9824282D0 (en) 1998-11-05 1998-12-30 Microbiological Research Agenc Delivery of superoxide dismutase to neuronal cells
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells

Also Published As

Publication number Publication date
US7452543B2 (en) 2008-11-18
EP0996468B1 (de) 2003-05-21
DE69814858T2 (de) 2004-03-11
ZA989138B (en) 1999-05-27
US20060121056A1 (en) 2006-06-08
EP0996468A1 (de) 2000-05-03
CA2306350A1 (en) 1999-04-15
AU9357498A (en) 1999-04-27
ES2198750T3 (es) 2004-02-01
DK0996468T3 (da) 2003-09-15
ATE240747T1 (de) 2003-06-15
US7052702B1 (en) 2006-05-30
GB9721189D0 (en) 1997-12-03
PT996468E (pt) 2003-09-30
WO1999017806A1 (en) 1999-04-15
CA2306350C (en) 2008-09-02
AU741456B2 (en) 2001-11-29
JP2001518522A (ja) 2001-10-16
JP4629225B2 (ja) 2011-02-09

Similar Documents

Publication Publication Date Title
DE69814858D1 (de) Galaktose-bindende lektine konjugate mit clostridiale neurotoxine ,wie analgetika
MXPA03000576A (es) Motivo a base de leucina y neurotoxinas clostridial.
CO5170431A1 (es) Preparacion farmaceutica que contiene una de las neurotoxinas botulinicas de clostridium botulinum de los tipos a,b,c,d,e,f, o g, o una mezcla de dos o mas de estas neuroxinas
TR199701705T1 (xx) Trigliserid ya�lar�n i�lenmesinde hareketsiz enzim ve kullan�m�.
DE69830743D1 (de) Protease-varianten und zusammensetzungen
PL323006A1 (en) Derivatives of toxin clostridium capable to modify peripheral functions of afferent sensory fibres
WO2001077951A8 (en) System and methods for group retirement plan administration
PT1311504E (pt) Tetrazolil-fenil-acetamidas activadoras da glucoquinase
ES2139369T5 (es) Disposicion de bisagra con efecto resorte, por ejemplo para cierres de plastico inyectado de una sola pieza.
DE60028359D1 (de) Chromogenes medium zum nachweis von staphylococcus aureus
DK0832250T3 (da) Mutant alfa-amylase
DK0763131T3 (da) Assay for tetanus- og botulinumtoksiner
ATE244003T1 (de) Transdermales therapeutisches system
WO2002040506A3 (en) Modified clostridial neurotoxins with altered biological persistence
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
ATE358473T1 (de) Diamino-propanol-verbindungen zur behandlung von ischaemien
BR9604825A (pt) Citostáticos modificados por carboidratos
DK1234043T3 (da) Konstruktion for afgivelse af terapeutiske midler til neuroceller
AU2003295769A1 (en) Treatment of mammalian reaction to ige interactions
UA32522C2 (uk) Ліофілізована протипухлинна композиція і стерильна водна композиція для ін'єкцій на її основі
Müller et al. Morphological changes of cultured endothelial cells after microinjection of toxins that act on the cytoskeleton
DK177791A (da) Tensidfrie, faste enzympraeparater omfattende protease som virksomt enzym
AU1885700A (en) Device for holding socks or stockings in pairs
FR2789918B1 (fr) Dispositif de rupture controlee d'une structure travaillant a la traction et equipement en faisant application
Sanchez Mutalysins

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: THE SPEYWOOD LABORATORY LTD., LONDON, GB

Owner name: HEALTH PROTECTION AGENCY, SALISBURY, WILTSHIRE, GB

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: IPSEN LTD., BERKSHIRE, GB

Owner name: HEALTH PROTECTION AGENCY, SALISBURY, WILTSHIRE, GB

8327 Change in the person/name/address of the patent owner

Owner name: SYNTAXIN LTD., ABINGDON, OXFORDSHIRE, GB